touchPANEL DISCUSSION Current and future best practice for the management of non-cystic fibrosis bronchiectasis
Experts discuss best practice management options for patients with non-cystic fibrosis bronchiectasis.
Dr Charles Daley
National Jewish Health, Denver, CO, USA
CHAIR
Panelists:
Introduction
Chair, Dr Charles Daley, introduces the expert panel and agenda for this discussion on best practice management of non-cystic fibrosis bronchiectasis.
view bio and disclosures 1/4 Next ChapterDisease prevalence and risk factors for acute exacerbations
The panel discuss the prevalence of non-cystic fibrosis bronchiectasis and the burden of disease, including key signs and symptoms, and the impact of acute exacerbations on the quality of life of patients with non-cystic fibrosis bronchiectasis.
view bio and disclosures 2/4 Next ChapterManagement of chronic infection
The panel consider treatment options for chronic infections in patients with non-cystic fibrosis bronchiectasis and discuss the role of eradication protocols in managing chronic infections.
view bio and disclosures 3/4 Next ChapterAvailable and emerging pharmacotherapeutic strategies
The panel share their insights on how to select the optimum treatment for patients with non-cystic fibrosis bronchiectasis and consider potential future treatments.
view bio and disclosures 4/4 Take CE/CME TestOverview & Learning Objectives
Overview
In this activity, the expert panel discuss three clinical themes covering the disease prevalence and risk factors for acute exacerbations, the management of chronic infection, and available and emerging pharmacotherapeutic strategies to optimize the management of patients with non-cystic fibrosis bronchiectasis.
This activity is jointly provided by USF Health and touchIME. read more
Target Audience
This activity has been designed to meet the educational needs of respiratory care specialists and respiratory paediatricians involved in the management of patients with non-cystic fibrosis bronchiectasis.
Disclosures
USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education.
All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.
Faculty
Dr Charles Daley discloses: Advisory board or panel fees from AN2 Therapeutics, AstraZeneca, Insmed, Matinas, Paratek, Pfizer, Renovion and Spero. Consultancy fees from AN2 Therapeutics, Genentech, Paratek and Renovion. Grants/research support from AN2 Therapeutics, Bugworks, Insmed, Paratek and Renovion.
Prof. Stefano Aliberti discloses: Advisory board or panel fees from AstraZeneca UK Ltd (relationship terminated), Insmed, and Insmed Italy Srl (relationship terminated). Consultancy fees from Grifols Shared Services North America Inc., Fondazione Internazionale Menarini, Insmed Ireland Ltd, Insmed Italy Srl and Zambon Spa (relationships terminated with all companies). Grants/research support from Fisher & Paykel and Insmed. Speaker’s bureau fees from CSL Behring GmbH, GlaxoSmithKline SpA and Insmed Italy Srl (relationships terminated with all companies).
Dr Anne O’Donnell discloses: Advisory board or panel fees from AstraZeneca, Boehringer Ingelheim, Electromed, Insmed, Paratek, Xellia (relationship terminated) and Zambon. Grants/research support from AstraZeneca, Insmed, Paratek, Redhill Biopharma and Zambon.
Content reviewer
Dr Debabrata Bandyopadhya, MBBS, MD, FRCP, FACP, FCCP has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Director
Katrina Lester and Hannah Fisher have no financial interests/relationships or affiliations in relation to this activity.
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
If you have questions regarding credit please contact cpdsupport@usf.edu.
Accreditations
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Advanced Practice Providers
Physician Assistants may claim a maximum of 0.75 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Date of original release: 24 May 2022. Date credits expire: 24 May 2023.
If you have any questions regarding credit please contact cpdsupport@usf.edu.
Learning Objectives
After watching this activity, participants should be better able to:
- Review the incidence, causes and risk factors for non-cystic fibrosis bronchiectasis
- Discuss eradication protocols for infection in patients with non-cystic fibrosis bronchiectasis
- Evaluate available and emerging pharmacotherapeutic treatments for non-cystic fibrosis bronchiectasis
Faculty & Disclosures
Dr Charles Daley
National Jewish Health and University of Colorado, Denver, CO, USA
Icahn School of Medicine at Mount Sinai, New York, NY, USA
Charles Daley is chief of the Division of Mycobacterial and Respiratory Infections at National Jewish Health (NJH) and professor of medicine at NJH, the University of Colorado, and Icahn School of Medicine at Mount Sinai. read more
Dr Daley has served on and chaired expert panels for the World Health Organization, Centers for Disease Control and Prevention, Infectious Diseases Society of America and American Thoracic Society. He has participated in multiple guideline panels for these organizations. He recently chaired the revision of the multi-society sponsored Non-tuberculous Mycobacterial Pulmonary Disease Treatment Guideline.
Dr Daley was awarded the World Lung Health Award by the American Thoracic Society for his work in multidrug-resistant tuberculosis. Dr Daley served as the inaugural chair of the Bronchiectasis Research Registry. He was previously associate editor of the American Journal of Respiratory and Critical Care Medicine and is currently associate editor of the European Respiratory Journal. His academic interests include tuberculosis global health policy and clinical and translational research related to tuberculosis, non-tuberculous mycobacterial infections and bronchiectasis.
Dr Charles Daley discloses: Advisory board or panel fees from AN2 Therapeutics, AstraZeneca, Insmed, Matinas, Paratek, Pfizer, Renovion and Spero. Consultancy fees from AN2 Therapeutics, Genentech, Paratek and Renovion. Grants/research support from AN2 Therapeutics, Bugworks, Insmed, Paratek and Renovion.
Prof. Stefano Aliberti
Humanitas University and Humanitas Research Hospital, Milan, Italy
Stefano Aliberti is professor of respiratory medicine at Humanitas University and director of the Respiratory Department at the Humanitas Research Hospital in Milan, Italy. He is also leading the bronchiectasis and non-tuberculous mycobacteria programmes at the Humanitas Research Hospital. read more
Prof. Aliberti has extensive experience in epidemiological and clinical research in pneumonia since the early 2000s when he was working for the Community-Acquired Pneumonia Organization at the Division of Infectious Diseases at the University of Louisville, KY, USA.
Over the past 15 years, Prof. Aliberti has been heavily involved in chronic respiratory infection research, including bronchiectasis and non-tuberculous mycobacteria, and received the Young Researcher Award in Respiratory Infections from the European Respiratory Society (ERS) for his contribution to community-acquired pneumonia. He founded the European Bronchiectasis Registry and is the chair of both the Italian Bronchiectasis Registry and the Italian Registry of Pulmonary Non-Tuberculous Mycobacteria. He is also chair of the ERS END-COVID clinical research collaboration. Prof. Aliberti has been an active member in different international societies over the past decade, including ERS, American College of Chest Physicians and the European Cystic Fibrosis Society. Prof. Aliberti has been involved in the development of guidelines on bronchiectasis, COVID-19 and severe pneumonia, as well as statements on tuberculosis. He is also associate editor (chest infections) for CHEST.
Prof. Aliberti’s major clinical and research interests are in both acute and chronic respiratory infections.
Prof. Stefano Aliberti discloses: Advisory board or panel fees from AstraZeneca UK Ltd (relationship terminated), Insmed, and Insmed Italy Srl (relationship terminated). Consultancy fees from Grifols Shared Services North America Inc., Fondazione Internazionale Menarini, Insmed Ireland Ltd, Insmed Italy Srl and Zambon Spa (relationships terminated with all companies). Grants/research support from Fisher & Paykel and Insmed. Speaker’s bureau fees from CSL Behring GmbH, GlaxoSmithKline SpA and Insmed Italy Srl (relationships terminated with all companies).
Dr Anne O’Donnell
Georgetown University, Washington, DC, USA
Anne O’Donnell is professor of medicine and the Nehemiah and Naomi Cohen chair in pulmonary disease research at Georgetown University Medical Center, Washington DC, USA. She is also the chief, Division of Pulmonary, Critical Care and Sleep Medicine. read more
Dr O’Donnell is board certified in pulmonary medicine, critical care, sleep medicine and internal medicine. Her clinical and research activities focus on the care of patients with non-cystic fibrosis bronchiectasis and related infections. She has a long track record of publications and leadership in clinical trials for bronchiectasis and associated infections.
Dr Anne O’Donnell discloses: Advisory board or panel fees from AstraZeneca, Boehringer Ingelheim, Electromed, Insmed, Paratek, Xellia (relationship terminated) and Zambon. Grants/research support from AstraZeneca, Insmed, Paratek, Redhill Biopharma and Zambon.
Register to touchRESPIRATORY for FREE
- Peer-reviewed journals and expert opinions
- Interactive CME and e-learning modules
- Video conference highlights
